

General information about company		
Scrip code*		530125
NSE Symbol*		NOTLISTED
MSEI Symbol*		NOTLISTED
ISIN*		INE103E01016
Name of company		Samrat Pharmachem Limited
Type of company		Main Board
Class of security		Equity
Date of start of financial year		01-04-2024
Date of end of financial year		31-03-2025
Date of board meeting when results were approved		30-05-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange		26-03-2025
Description of presentation currency		INR
Level of rounding		Lakhs
Reporting Type		Quarterly
Reporting Quarter		Fourth quarter
Nature of report standalone or consolidated		Standalone
Whether results are audited or unaudited for the quarter ended		Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended		Audited
Segment Reporting		Single segment
Description of single segment		Pharmaceutical Chemicals
Start date and time of board meeting		30-05-2025 14:00
End date and time of board meeting		30-05-2025 20:30
Whether cash flow statement is applicable on company		Yes
Type of cash flow statement		Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion
Whether the company has any related party?		No
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure?		No
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public		NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of bank's staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure.		NA
(III) Whether the company is a 'high value debt listed entity' according to regulation 15 (1A)?		No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?		
(b) If answer to above question is No, please explain the reason for not complying.		
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company?		Yes
Latest Date on which RPT policy is updated		17-04-2025
Indicate Company website link for updated RPT policy of the Company		www.samratpharmachem.com
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter?		No
No. of times funds raised during the quarter		
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity?	No	There are no defaults in payment of Loans

Financial Results – Ind-AS				
Particulars		3 months/ 6 months ended (dd-mm-yyyy)	Year to date figures for current period ended (dd-mm-yyyy)	
Date of start of reporting period		01-01-2025	01-04-2024	
Date of end of reporting period		31-03-2025	31-03-2025	
Whether results are audited or unaudited		Unaudited	Audited	
Nature of report standalone or consolidated		Standalone	Standalone	
Part I	Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.			
1	Income			
	Revenue from operations	7120.31	28586.05	
	Other income	-10.73	97.34	
	Total income	7109.58	28683.39	
2	Expenses			
(a)	Cost of materials consumed	6262.93	26927.1	
(b)	Purchases of stock-in-trade	0	0	
(c)	Changes in inventories of finished goods, work-in-progress and stock-in-trade	615.65	-252.49	
(d)	Employee benefit expense	65.57	222.09	
(e)	Finance costs	22.16	67.41	
(f)	Depreciation, depletion and amortisation expense	16.04	65.47	
(g)	Other Expenses			
1	Manufacturing, Administration, Selling & DistributionExpense	163.58	665.2	
	Total other expenses	163.58	665.2	
	Total expenses	7145.93	27694.78	
3	Total profit before exceptional items and tax	-36.35	988.61	
4	Exceptional items	0	0	
5	Total profit before tax	-36.35	988.61	
6	Tax expense			
7	Current tax	8.58	299.92	
8	Deferred tax	-5.01	-22.53	
9	Total tax expenses	3.57	277.39	
10	Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement	0	0	
11	Net Profit Loss for the period from continuing operations	-39.92	711.22	
12	Profit (loss) from discontinued operations before tax	0	0	
13	Tax expense of discontinued operations	0	0	
14	Net profit (loss) from discontinued operation after tax	0	0	
15	Share of profit (loss) of associates and joint ventures accounted for using equity method	0	0	
16	Total profit (loss) for period	-39.92	711.22	
17	Other comprehensive income net of taxes	0	0	
18	Total Comprehensive Income for the period	-39.92	711.22	
19	Total profit or loss, attributable to			
	Profit or loss, attributable to owners of parent			
	Total profit or loss, attributable to non-controlling interests			
20	Total Comprehensive income for the period attributable to			
	Comprehensive income for the period attributable to owners of parent			
	Total comprehensive income for the period attributable to owners of parent non-controlling interests			
21	Details of equity share capital			
	Paid-up equity share capital	308.97	308.97	

	Face value of equity share capital	10	10	
22	Reserves excluding revaluation reserve		0	
23	Earnings per share			
i	Earnings per equity share for continuing operations			
	Basic earnings (loss) per share from continuing operations	-1.29	23.02	
	Diluted earnings (loss) per share from continuing operations	-1.29	23.02	
ii	Earnings per equity share for discontinued operations			
	Basic earnings (loss) per share from discontinued operations	0	0	
	Diluted earnings (loss) per share from discontinued operations	0	0	
iii	Earnings per equity share (for continuing and discontinued operations)			
	Basic earnings (loss) per share from continuing and discontinued operations	-1.29	23.02	
	Diluted earnings (loss) per share from continuing and discontinued operations	-1.29	23.02	
24	Debt equity ratio			Textual Information( 1)
25	Debt service coverage ratio			Textual Information( 2)
26	Interest service coverage ratio			Textual Information( 3)
27	Disclosure of notes on financial results	Textual Information(4)		

Text Block	
Textual Information(4)	<div>1. The above results were reviewed by the Audit Committee of the Board of Directors.</div> <div>2. The above results have been taken on record by the Board of Directors at it Meeting held on Friday, May 30, 2025 at the Corporate Office of the Company.</div> <div>3. The Company manufactures pharmaceutical chemicals, which is a single business segment.</div> <div>4. The figures for the previous period have been regrouped where necessary to conform to current period's classification.</div>

Statement of Asset and Liabilities		
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2024
Date of end of reporting period		31-03-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
	Assets	
1	Non-current assets	
	Property, plant and equipment	1046.5
	Capital work-in-progress	
	Investment property	
	Goodwill	0
	Other intangible assets	1.46
	Intangible assets under development	
	Biological assets other than bearer plants	
	Investments accounted for using equity method	
	Non-current financial assets	
	Non-current investments	343.97
	Trade receivables, non-current	
	Loans, non-current	27.32
	Other non-current financial assets	394.11
	Total non-current financial assets	765.4
	Deferred tax assets (net)	
	Other non-current assets	0
	Total non-current assets	1813.36
2	Current assets	
	Inventories	3800.53
	Current financial asset	
	Current investments	35.96
	Trade receivables, current	5653.57
	Cash and cash equivalents	4.83
	Bank balance other than cash and cash equivalents	11.64
	Loans, current	0
	Other current financial assets	1.79
	Total current financial assets	5707.79
	Current tax assets (net)	
	Other current assets	827.73
	Total current assets	10336.05
3	Non-current assets classified as held for sale	
4	Regulatory deferral account debit balances and related deferred tax Assets	
	Total assets	12149.41
	Total current assets	10336.05
3	Non-current assets classified as held for sale	
4	Regulatory deferral account debit balances and related deferred tax Assets	
	Total assets	12149.41
	Equity and liabilities	
1	Equity	
	Equity attributable to owners of parent	
	Equity share capital	308.97
	Other equity	6871.05

	<b>Total equity attributable to owners of parent</b>	7180.02
	Non controlling interest	
	<b>Total equity</b>	7180.02
<b>2</b>	<b>Liabilities</b>	
	<b>Non-current liabilities</b>	
	<b>Non-current financial liabilities</b>	
	Borrowings, non-current	0
	<b>Trade Payables, non-current</b>	
	(A) Total outstanding dues of micro enterprises and small enterprises	
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	
	<b>Total Trade payable</b>	
	Other non-current financial liabilities	
	<b>Total non-current financial liabilities</b>	0
	Provisions, non-current	0
	Deferred tax liabilities (net)	11.11
	Deferred government grants, Non-current	
	Other non-current liabilities	
	<b>Total non-current liabilities</b>	11.11
	<b>Current liabilities</b>	
	<b>Current financial liabilities</b>	
	Borrowings, current	991.49
	<b>Trade Payables, current</b>	
	(A) Total outstanding dues of micro enterprises and small enterprises	0
	(B) Total outstanding dues of creditors other than micro enterprises and small enterprises	3856.15
	<b>Total Trade payable</b>	3856.15
	Other current financial liabilities	13.8
	<b>Total current financial liabilities</b>	4861.44
	Other current liabilities	0.22
	Provisions, current	2.49
	Current tax liabilities (Net)	94.13
	Deferred government grants, Current	
	<b>Total current liabilities</b>	4958.28
3	Liabilities directly associated with assets in disposal group classified as held for sale	
4	Regulatory deferral account credit balances and related deferred tax liability	
	<b>Total liabilities</b>	4969.39
	<b>Total equity and liabilities</b>	12149.41
	<b>Disclosure of notes on assets and liabilities</b>	<b>Textual Information(1)</b>

Other Comprehensive Income			
Date of start of reporting period		01-01-2025	01-04-2024
Date of end of reporting period		31-03-2025	31-03-2025
Whether results are audited or unaudited		Unaudited	Audited
Nature of report standalone or consolidated		Standalone	Standalone
	Other comprehensive income [Abstract]		
1	Amount of items that will not be reclassified to profit and loss		
	Total Amount of items that will not be reclassified to profit and loss		
2	Income tax relating to items that will not be reclassified to profit or loss		
3	Amount of items that will be reclassified to profit and loss		
	Total Amount of items that will be reclassified to profit and loss		
4	Income tax relating to items that will be reclassified to profit or loss		
5	Total Other comprehensive income		

Cash flow statement, indirect		
Particulars		Year ended (dd-mm-yyyy)
Date of start of reporting period		01-04-2024
Date of end of reporting period		31-03-2025
Whether results are audited or unaudited		Audited
Nature of report standalone or consolidated		Standalone
Part I	Blue color marked fields are non-mandatory.	
1	Statement of cash flows	
	Cash flows from used in operating activities	
	Profit before tax	988.61
2	Adjustments for reconcile profit (loss)	
	Adjustments for finance costs	67.41
	Adjustments for decrease (increase) in inventories	-1732.84
	Adjustments for decrease (increase) in trade receivables, current	1274.45
	Adjustments for decrease (increase) in trade receivables, non-current	0
	Adjustments for decrease (increase) in other current assets	-602.49
	Adjustments for decrease (increase) in other non-current assets	0
	Adjustments for other financial assets, non-current	71.23
	Adjustments for other financial assets, current	0
	Adjustments for other bank balances	-5.39
	Adjustments for increase (decrease) in trade payables, current	-910.69
	Adjustments for increase (decrease) in trade payables, non-current	0
	Adjustments for increase (decrease) in other current liabilities	0
	Adjustments for increase (decrease) in other non-current liabilities	-4.04
	Adjustments for depreciation and amortisation expense	65.47
	Adjustments for impairment loss reversal of impairment loss recognised in profit or loss	0
	Adjustments for provisions, current	0
	Adjustments for provisions, non-current	2.49
	Adjustments for other financial liabilities, current	0
	Adjustments for other financial liabilities, non-current	-9.89
	Adjustments for unrealised foreign exchange losses gains	0
	Adjustments for dividend income	0
	Adjustments for interest income	0
	Adjustments for share-based payments	0
	Adjustments for fair value losses (gains)	0
	Adjustments for undistributed profits of associates	0
	Other adjustments for which cash effects are investing or financing cash flow	0
	Other adjustments to reconcile profit (loss)	0
	Other adjustments for non-cash items	-31.28
	Share of profit and loss from partnership firm or association of persons or limited liability partnerships	0
	Total adjustments for reconcile profit (loss)	-1815.57
	Net cash flows from (used in) operations	-826.96
	Dividends received	-2.72
	Interest paid	0
	Interest received	-34.22
	Income taxes paid (refund)	145.24
	Other inflows (outflows) of cash	0
	Net cash flows from (used in) operating activities	-1009.14
3	Cash flows from used in investing activities	
	Cash flows from losing control of subsidiaries or other businesses	0
	Cash flows used in obtaining control of subsidiaries or other businesses	0

	Other cash receipts from sales of equity or debt instruments of other entities	4127.9
	Other cash payments to acquire equity or debt instruments of other entities	4174.62
	Other cash receipts from sales of interests in joint ventures	0
	Other cash payments to acquire interests in joint ventures	0
	Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships	0
	Cash payment for investment in partnership firm or association of persons or limited liability partnerships	0
	Proceeds from sales of property, plant and equipment	-9.51
	Purchase of property, plant and equipment	41.2
	Proceeds from sales of investment property	0
	Purchase of investment property	0
	Proceeds from sales of intangible assets	0
	Purchase of intangible assets	0
	Proceeds from sales of intangible assets under development	0
	Purchase of intangible assets under development	0
	Proceeds from sales of goodwill	0
	Purchase of goodwill	0
	Proceeds from biological assets other than bearer plants	0
	Purchase of biological assets other than bearer plants	0
	Proceeds from government grants	0
	Proceeds from sales of other long-term assets	0
	Purchase of other long-term assets	0
	Cash advances and loans made to other parties	0
	Cash receipts from repayment of advances and loans made to other parties	0
	Cash payments for future contracts, forward contracts, option contracts and swap contracts	0
	Cash receipts from future contracts, forward contracts, option contracts and swap contracts	0
	Dividends received	2.72
	Interest received	34.22
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	60
	<b>Net cash flows from (used in) investing activities</b>	<b>-0.49</b>
<b>4</b>	<b>Cash flows from used in financing activities</b>	
	Proceeds from changes in ownership interests in subsidiaries	0
	Payments from changes in ownership interests in subsidiaries	0
	Proceeds from issuing shares	0
	Proceeds from issuing other equity instruments	0
	Payments to acquire or redeem entity's shares	0
	Payments of other equity instruments	0
	Proceeds from exercise of stock options	0
	Proceeds from issuing debentures notes bonds etc	0
	Proceeds from borrowings	146.02
	Repayments of borrowings	0
	Payments of lease liabilities	0
	Dividends paid	30.9
	Interest paid	67.41
	Income taxes paid (refund)	0
	Other inflows (outflows) of cash	0
	<b>Net cash flows from (used in) financing activities</b>	<b>47.71</b>
	<b>Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes</b>	<b>-961.92</b>
<b>5</b>	<b>Effect of exchange rate changes on cash and cash equivalents</b>	
	Effect of exchange rate changes on cash and cash equivalents	0
	<b>Net increase (decrease) in cash and cash equivalents</b>	<b>-961.92</b>
	Cash and cash equivalents cash flow statement at beginning of period	966.75
	<b>Cash and cash equivalents cash flow statement at end of period</b>	<b>4.83</b>

Details of Impact of Audit Qualification			
Whether results are audited or unaudited		Audited	
Declaration of unmodified opinion or statement on impact of audit qualification		Declaration of unmodified opinion	
Auditor's opinion			
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results		Yes	
	Audit firm's name	Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI	Certificate valid upto
1	Shah & Savla LLP	Yes	30-04-2027